Last reviewed · How we verify
NCT06865846: THReshOld
Treatment Hypertension to Recommended Levels in Old Patients
NA trial testing TeleMedBot in Arterial Hypertension in 60 participants. Enrolling by invitation.
1 June 2025
Quick facts
| Lead sponsor | I.M. Sechenov First Moscow State Medical University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 April 2024 |
| Primary completion | 1 June 2025 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- TeleMedBot
Conditions studied
- Arterial Hypertension — all drugs for Arterial Hypertension →
Sponsor
I.M. Sechenov First Moscow State Medical University
Who can join
65 and older, any sex, with Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
After checking the patient characteristics to the inclusion and exclusion criteria, and confirming the ability to complete the questionnaires provided by the study protocol, patients will be randomly assigned to 2 groups: a group with a higher target BP level (less than 135 mmHg) and a lower target BP level (less than 125 mmHg). Achievement of target BP levels will be assessed using a remote monitoring system. The study will identify factors that prevent achievement of target BP levels, as well as assess the efficacy, safety and tolerability of antihypertensive therapy (AHT).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06865846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Arterial Hypertension
Currently open trials in the same condition.
- NCT06769269 — Hypertension Registry: Study of Primary and Secondary Hypertension Phenotypes, Complications, and Treatment Personalizat · recruiting
- NCT07303556 — Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs · NA · active not recruiting
- NCT06828211 — Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD · NA · active not recruiting
- NCT07049289 — Telemonitoring in Arterial Hypertension · NA · active not recruiting
- NCT06722625 — Telemedical Algorithm-Supported Care for Hypertension · NA · recruiting
Other I.M. Sechenov First Moscow State Medical University trials
Trials by the same sponsor.
- NCT07348991 — Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG · not yet recruiting
- NCT07412457 — Guideline Adherence in Dyslipidemia With Clinical Decision Support · not yet recruiting
- NCT07396792 — Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram · not yet recruiting
- NCT07412418 — Screening for Pulmonary Embolism Using Single-channel Electrocardiogram · not yet recruiting
- NCT07518550 — Maternal and Fetal Electrocardiograms Separation Algorithm · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06865846 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by I.M. Sechenov First Moscow State Medical University
- Last refreshed: 10 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06865846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing